We are live on
!
Find out more
CG
Carlyle Group Portfolio holdings
AUM
$10.6B
1-Year Est. Return
11.25%
This Fund
S&P 500
This Quarter
Est. Return
+7.47%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$3.8B
AUM Growth
-$345M
(-8.3%)
Cap. Flow
+$3.37B
Cap. Flow
% of AUM
88.64%
Top 10 Holdings %
Top 10 Hldgs %
99.33%
Holding
27
New
–
Increased
1
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SARO
StandardAero Inc
SARO
|
+$3.4B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLNO
Soleno Therapeutics
SLNO
|
+$25.1M |
| 2 |
Getty Images
GETY
|
+$5.83M |
| 3 |
EM
Smart Share Global Ltd
EM
|
+$493K |
| 4 |
Riley Exploration Permian
REPX
|
+$315K |
| 5 |
Robinhood
HOOD
|
+$233K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 94.35% |
| 2 | Healthcare | 2.64% |
| 3 | Technology | 1.87% |
| 4 | Real Estate | 0.69% |
| 5 | Communication Services | 0.28% |
Similar funds
SGA
PF
BMSSC
EAM
WAM
HTC
CA
OIA
Carlyle Group's Q1 2025 Portfolio in Review
As of Q1 2025, Carlyle Group held 27 positions worth $3.8B, down 8.3% from $4.15B the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Carlyle Group deployed $3.37B of net new capital in Q1 2025, adding to 1 existing holding.
By sector, the portfolio is most concentrated in Industrials at 94% of assets, up from 94% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Soleno Therapeutics, an estimated $25.1M trimmed.
- Carlyle Group added most to StandardAero Inc in Q1 2025, an estimated $3.4B increase.
- Carlyle Group's biggest Q1 2025 reduction was Soleno Therapeutics, cutting an estimated $25.1M.
- Carlyle Group fully exited Riley Exploration Permian in Q1 2025, selling an estimated $315K.
- Carlyle Group's ten largest holdings make up 99% of its $3.8B portfolio in Q1 2025.
- Carlyle Group opened 0 new positions and closed 4 in Q1 2025.
- Carlyle Group's portfolio value fell 8.3% quarter-over-quarter to $3.8B.
Based on Carlyle Group's 13F filing for Q1 2025, filed 9 May 2025.